bromocriptine

(redirected from Cycloset)
Also found in: Dictionary, Medical.
Related to Cycloset: bromocriptine

bromocriptine

[‚brō·mō′krip‚tēn]
(organic chemistry)
C32H40BrN5O5 A polypeptide alkaloid that is a derivative of the ergotoxin group of ergot alkaloids and is a dopamine receptor agonist.
Mentioned in ?
References in periodicals archive ?
CYCLOSET is a dopamine receptor agonist, and may, therefore, potentiate the risk for syncope in these patients.
Assess orthostatic vital signs prior to initiation of CYCLOSET and periodically thereafter.
7) In the Cycloset Safety Study, for instance, bromocriptine QR combined with standard diabetes therapy (diet plus oral hypoglycemic agents as needed) was compared with standard diabetes therapy plus placebo in more than 3,000 patients.
Cycloset is taken by mouth once daily in the morning, and results in a "brief pulse of dopamine agonist activity shortly after its administration," which improves postprandial glucose without increasing plasma insulin concentrations, according to a statement issued by VeroScience.
But unlike its older parent, Cycloset is formulated to require a low, quick-acting dose taken just in the morning -- no other time of day.
Cycloset is the first drug to win FDA approval under new guidelines that require better evidence that diabetes treatments are heart-safe.
Following six months of therapy, patients who received Cycloset reduced daily insulin requirements by approximately 25% on average (P<0.
The current study findings are consistent with previous basic and clinical science studies indicating that Cycloset may improve insulin action.
In assessing cardiovascular safety in type 2 diabetes subjects, CYCLOSET demonstrated a significant 52% relative risk reduction in cardiovascular events (composite endpoint of myocardial infarction, stroke and cardiovascular death) compared with placebo
CYCLOSET is a unique, quick release form of bromocriptine, a dopamine D2 receptor agonist, and is approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
8 million for the third quarter of 2012 included royalties on GLUMETZA net sales, the gross margin split on CYCLOSET net sales, royalties on ZEGERID net sales and amortization of upfront payments.
CYCLOSET (bromocriptine mesylate) tablets new prescriptions increased 131% and total prescriptions were up 100% in the second quarter of 2012 compared with the second quarter of 2011.